^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DNA polymerase inhibitor

    Related drugs:
    3d
    Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors (clinicaltrials.gov)
    P1, N=11, Not yet recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jan 2031 --> Jun 2031 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2031 --> Jun 2031
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    valacyclovir
    17d
    Tazemetostat and Palbociclib With CPX-351for R/R AML (clinicaltrials.gov)
    P1, N=24, Recruiting, Thomas Jefferson University | Suspended --> Recruiting | Trial completion date: Jan 2026 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Ibrance (palbociclib) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • Tazverik (tazemetostat)
    18d
    Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1 (clinicaltrials.gov)
    P2, N=54, Completed, University of North Carolina, Chapel Hill | Active, not recruiting --> Completed
    Trial completion
    23d
    IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya (clinicaltrials.gov)
    P1, N=120, Completed, Columbia University | Not yet recruiting --> Completed | Phase classification: PN/A --> P1
    Trial completion • Phase classification
    23d
    Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. (PubMed, J Antimicrob Chemother)
    A three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate maintained durable long-term viral suppression, while mitigating but not fully preventing toxicities associated with EFV/TDF/FTC. These findings support reduced-exposure antiretroviral therapy and warrant evaluation of similar strategies with modern integrase inhibitor-based regimens.
    Clinical • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    25d
    Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes. (PubMed, Hematology)
    sAML/AML-MRC with an adverse karyotype had a dismal outcome. These findings provide a benchmark for risk stratification in the pre- CPX-351 era.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    1m
    CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial. (PubMed, Blood Adv)
    The OS benefit of CPX-351 observed in the trial was driven by AML-MR with no benefit of CPX-351 in TP53-AML, where the primary prognostic factor was allelic state. Clinical Trial Information: NCT01696084.
    Journal
    |
    TP53 (Tumor protein P53) • DDX41 (DEAD-Box Helicase 41)
    |
    TP53 mutation
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    1m
    A Randomized Controlled Clinical Study on Transfer Factor Oral Solution in the Treatment of Herpes Zoster (ChiCTR2600117507)
    P4, N=90, Recruiting, Dermatology Hospital, Southern Medical University; Dermatology Hospital, Southern Medical University
    New P4 trial
    |
    valacyclovir
    1m
    Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy (clinicaltrials.gov)
    P2, N=84, Enrolling by invitation, Instituto Oncoclinicas
    New P2 trial
    |
    valacyclovir
    2ms
    Ultrasound-Guided Thoracic Paravertebral Block With Steroid and Local Anesthetic for Acute Herpes Zoster: Effects on Pain Control and Prevention of Postherpetic Neuralgia (clinicaltrials.gov)
    P3, N=100, Completed, Assiut University
    New P3 trial
    |
    valacyclovir
    3ms
    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=52, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Vanflyta (quizartinib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)